Trial Profile
A Phase 1, Randomized, Double-Blinded, Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study to Evaluate the Safety and Tolerability of SKL20540 in Healthy Subjects
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs SKL 15508 (Primary)
- Indications Cognition disorders
- Focus Adverse reactions
- Sponsors SK biopharmaceuticals
- 15 Nov 2018 New trial record